MLN8237 for Treatment of Participants With Ovarian, Fallopian Tube, or Peritoneal Carcinoma

NCT00853307 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

31

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Carcinoma

Interventions

DRUG: Alisertib

Sponsor

Millennium Pharmaceuticals, Inc.